All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
8 warning events since 2017; the latest 2025-06-23.
From the record
Aptevo Therapeutics Inc.'s filings since 2017 show 8 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 6 times, the latest 2025-05-22); an auditor change (8-K item 4.01, 2 times, the latest 2025-06-23) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-26.6% a year over 6 filed years; profitable in 2 of 6.
From the record
Aptevo Therapeutics Inc.'s 6 filed years say what it did: revenue went from $15 million in fiscal 2017 to $3 million in fiscal 2022, down 26.6% a year; it rose in 3 of 5 years; the deepest fall was 90% from fiscal 2019 to fiscal 2022; net income was positive in 2 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Aptevo Therapeutics Inc.'s shareholder treatment is put at 0.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 1% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -149%: lost 149¢ per shareholder dollar. Leverage 36%: owes 36¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Aptevo Therapeutics Inc. lost about 149 cents for every dollar of shareholders' money. Leverage: it owed about 36 cents per dollar of assets, and net share issuance: its share count grew 41038.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 46% of 315 in its family; net margin 257.8%.
From the record
Aptevo Therapeutics Inc.'s standing among 315 graded names in its industry family: revenue of $3 million in fiscal 2022 ranks in the bottom 31% by size; a net margin of 257.8% ranks in the top 2%; revenue growth of -54.2% a year over the last 3 filed years ranks in the bottom 7% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 36% of 315 in its family for leadership; chief executive since 2026.
From the record
Aptevo Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lamothe, Jeffrey G. (President and CEO, as filed), filing under that title since 2026-08-10, 3 months (bottom 3% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 10.3 years (top 7%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 5%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 8.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Aptevo Therapeutics Inc.'s room to expand is put at 8.1 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 19% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 24% of 306 in its family for growth drivers.
From the record
Aptevo Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2022: revenue grew -54.2% a year over the last three filed years against -26.6% over all 6, slowing (bottom 22% of its family); the newest year grew -74.7% (bottom 8%); research spending grew -6.7% a year (bottom 37%); capital spending grew -42.5% a year (bottom 27%) (its annual reports). Aptevo Therapeutics Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 38% of 233 in its family for expectations against reality.
From the record
Aptevo Therapeutics Inc.'s newest year against its own record: revenue of $3 million in fiscal 2022 came in 58.9% below the $8 million its prior three years' pace pointed to (bottom 17% of its family); net income of $8 million against a prior three-year average of $29 million (top 12%); a net margin of more than its whole revenue against losses larger than its revenue before (top 20%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made